Spun out of University of Côte d’Azur and Inserm, InnoSkel expects to fund clinical work to address a form of skeletal dysplasia that causes dwarfism.
InnoSkel, a France-based gene therapy spinout of University of Côte d’Azur and research institute Inserm targeting rare skeletal diseases, publicly launched today with €20m ($24.3m) of series A capital.
The round was co-led by life sciences-focused investment firm Vida Ventures and private equity firm Jeito Capital with participation from EU-backed regional investment fund Région Sud Investissement and asset management firm Turenne Group.
InnoSkel is working on gene therapies to address skeletal dysplasia, a group of genetic disorders that impede the infantile growth of bones and joints.
The series A capital will help prepare for clinical trials on InnoSkel’s lead program, targeting a skeletal disorder called Spondyloepiphyseal Dysplasia congenita (SEDc) that triggers dwarfism.
InnoSkel also intends to use series A capital to develop the rest of its skeletal disorder pipeline, in addition to expanding its management and lab operations.
InnoSkel’s founding CEO is Elvire Gouze, who leads…
